Replimune Group (NASDAQ:REPL) Shares Gap Up – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped up before the market opened on Monday . The stock had previously closed at $12.49, but opened at $12.97. Replimune Group shares last traded at $12.44, with a volume of 74,714 shares traded.

Wall Street Analyst Weigh In

REPL has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. BMO Capital Markets raised their target price on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $17.29.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a market cap of $849.74 million, a PE ratio of -4.07 and a beta of 1.26. The firm’s 50-day moving average is $12.25 and its 200 day moving average is $10.77.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, research analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insider Transactions at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds have recently bought and sold shares of the company. Quest Partners LLC boosted its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares during the last quarter. Creative Planning grew its stake in shares of Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after buying an additional 4,699 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after acquiring an additional 5,410 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.